Department of Pathology, Unit 53, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.
Cancer Biomark. 2012;12(6):207-18. doi: 10.3233/CBM-130316.
Information on hormone receptor and human epidermal growth factor receptor 2 (HER2) is important for making optimal therapeutic decisions for breast cancer patients. Discordance in these biomarkers between primary breast carcinomas and corresponding metastases is well documented and may lead to changes in management option. The underlying mechanisms of biomarker discordance are complicated and multifactorial. Whereas biologic evolution, intratumoral heterogeneity, and subclonal selection may account for discordance, variations in sampling, processing, staining procedure and interpretation are the important contributory yet controllable factors. This article reviews the effects of different factors on the biomarker discordance, the clinical significance and the importance of standardizing methodology and interpretation criteria.
激素受体和人表皮生长因子受体 2（HER2）的信息对于乳腺癌患者做出最佳治疗决策非常重要。原发性乳腺癌和相应转移灶之间这些生物标志物的不一致已有充分记录，并可能导致治疗选择的改变。生物标志物不一致的潜在机制很复杂，涉及多种因素。虽然生物学进化、肿瘤内异质性和亚克隆选择可能是导致不一致的原因，但采样、处理、染色程序和解释的差异是重要的但可控制的因素。本文综述了不同因素对生物标志物不一致的影响、临床意义以及标准化方法和解释标准的重要性。
